TAS-114

Drug Overview

The medication known as TAS-114 is a highly specialized, oral “Smart Drug” used in the treatment of advanced cancers. It is not a traditional chemotherapy that broadly kills all growing cells. Instead, it is a targeted metabolic inhibitor designed to work in tandem with other cancer medicines to make them more powerful and less toxic to the body.

Specifically, TAS-114 is a dual-action agent that focuses on two very important enzymes involved in how cells build and break down DNA. By controlling these enzymes, TAS-114 helps trap cancer cells in a state where they cannot repair themselves.

• Generic Name: TAS-114 (also referred to as a dUTPase/DPD inhibitor).
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: Dual dUTPase and Dihydropyrimidine Dehydrogenase (DPD) Inhibitor / Targeted Therapy.
• Route of Administration: Oral (Tablet).
• FDA Approval Status: Investigational. It is not yet FDA-approved for general use but is being studied in advanced Phase 1 and Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand TAS-114, it helps to imagine a cancer cell as a factory trying to print blueprints (DNA) to make new cells. TAS-114 acts like a double-agent that sabotages the printing press and the recycling bin at the same time.

1. Sabotaging the Blueprints (dUTPase Inhibition)

Cancer cells are often under stress and make mistakes when building DNA. One common mistake is the accidental use of a “wrong” building block called dUTP. Healthy cells use an enzyme called dUTPase to clean out these wrong blocks. TAS-114 blocks this enzyme.

• The Molecular Trap: When dUTPase is blocked, the “wrong” building blocks (dUTP) flood the cell.
• DNA Damage: The cancer cell accidentally uses these wrong blocks to build its DNA. When the cell tries to fix this mess, it ends up shredding its own DNA strands, leading to cell death.

2. Guarding the Medicine (DPD Inhibition)

Many cancers are treated with a drug called 5-FU or Capecitabine. Normally, a person’s liver uses an enzyme called DPD to break down these drugs very quickly, which means less medicine reaches the tumor and more waste products enter the blood.

• The Shield: TAS-114 blocks the DPD enzyme.
• Molecular Level Impact: This keeps the cancer-fighting medicine in the body longer and at higher levels. Because TAS-114 is “smart,” it helps concentrate the active medicine inside the tumor while potentially reducing the toxic waste that causes side effects in healthy tissue.

FDA-Approved Clinical Indications

Because TAS-114 is currently an investigational agent, it does not have official FDA-approved uses for the general public. It is, however, being tested for the following conditions:

Oncological Uses (In Clinical Trials):

• Advanced Solid Tumors: Used in combination with S-1 or Capecitabine for various cancers that have spread.
• Gastric (Stomach) Cancer: Studied for patients whose cancer has returned after initial treatments.
• Non-Small Cell Lung Cancer (NSCLC): Investigated as a way to increase the effectiveness of traditional chemotherapy.
• Pancreatic Cancer: Used to help overcome the natural resistance these tumors have to standard drugs.

Non-oncological Uses:

• There are currently no non-oncological uses for TAS-114.

Dosage and Administration Protocols

As an investigational drug, the dose of TAS-114 is strictly managed by trial doctors. It is unique because it is taken as a pill at home, usually following a specific “on and off” schedule.

Special Adjustments:

• Renal (Kidney) Insufficiency: Because TAS-114 is cleared through the kidneys, patients with lower kidney function require a significantly reduced dose to prevent the drug from building up to dangerous levels.
• Hepatic (Liver) Insufficiency: Since the drug interacts with liver enzymes (DPD), liver function is monitored weekly.

Clinical Efficacy and Research Results

Recent studies (2020-2025) have shown that TAS-114 can make “low-dose” chemotherapy work as well as “high-dose” treatments, but with fewer hospitalizations.

• Tumor Response: In Phase 1b trials for advanced solid tumors, approximately 25 percent of patients saw their tumors shrink significantly when TAS-114 was added to their standard treatment.
• Disease Control: In patients with gastric cancer, the “Disease Control Rate” (where the cancer either shrank or stopped growing) reached over 60 percent in specific study groups.
• Safety Efficiency: Research has shown that TAS-114 successfully lowered the level of DPD enzyme activity in patients by over 80 percent, proving the drug hits its molecular target effectively.
• Survival Data: While long-term survival rates are still being collected, early data suggests that the combination of TAS-114 with oral fluoropyrimidines can extend “Progression-Free Survival” by several months in resistant cases.

Safety Profile and Side Effects

TAS-114 is designed to be safer than traditional chemotherapy, but it can still cause side effects as the body adjusts to the changes in DNA metabolism.

Black Box Warning: There is no FDA Black Box Warning for TAS-114 at this time.

Common Side Effects (>10%):

• Nausea: Mild stomach upset shortly after taking the pill.
• Fatigue: A general sense of tiredness.
• Decreased Appetite: A temporary loss of interest in food.
• Diarrhea: Soft or frequent stools.

Serious Adverse Events:

• Hematological Toxicity: A drop in white blood cells (increasing infection risk) or platelets (increasing bleeding risk).
• Skin Reactions: Such as “Hand-Foot Syndrome,” where the palms and soles become red and painful.
• Corneal Epithelial Damage: Rare issues with the surface of the eye, which can cause blurry vision.

Management Strategies:

• For Skin Issues: Use thick, fragrance-free moisturizing creams on hands and feet twice daily.
• For Nausea: Standard anti-nausea medications are usually very effective.
• For Eye Health: Patients are often advised to use preservative-free artificial tears and avoid wearing contact lenses during treatment.

Research Areas

TAS-114 is at the center of research regarding Metabolic Reprogramming. Scientists are currently looking into whether TAS-114 can be combined with Immunotherapy. The theory is that by causing DNA damage inside the tumor (through dUTPase inhibition), the cancer cell will “look” more dangerous to the immune system. This could help “waken up” T-cells to attack the tumor more aggressively.

In the field of Regenerative Medicine, researchers are studying how dUTPase inhibitors affect healthy stem cells. The goal is to ensure that while the drug sabotages cancer DNA, the body’s natural regenerative cells in the bone marrow remain protected.

Patient Management and Practical Recommendations

To ensure safety and the best treatment outcome, patients must be very precise with how they take TAS-114.

Pre-treatment Tests to be Performed:

• Kidney Function (Creatinine/GFR): Essential for determining the starting dose.
• Baseline Blood Count: To ensure blood levels are safe for treatment.
• Eye Exam: Some trials require a baseline check of the cornea.

Precautions During Treatment:

• Sun Sensitivity: This drug may make your skin more sensitive to the sun. Wear sunscreen and protective clothing.
• Monitor Vision: Report any new blurriness or “gritty” feeling in the eyes immediately.

“Do’s and Don’ts” List:

• DO take the medication at the same time every day to keep levels steady.
• DO report any fever over 100.4 degrees F (38 degrees C) immediately to your oncology team.
• DON’T skip doses. If you miss a dose, do not take two at the next scheduled time.
• DON’T start any new herbal supplements without asking your doctor, as they can interfere with liver enzymes.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. TAS-114 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.